NEW YORK (360Dx) – Quidel announced late Tuesday that its test to detect and differentiate influenza types A and B has met the US Food and Drug Administration's criteria to be reclassified as a class II rapid influenza diagnostic test and that the test has received 510(k) clearance.

The QuickVue Influenza A+B assay, which was previously CLIA waived, allows for qualitative, 10-minute detection of influenza A and B antigens directly from symptomatic patients' nasal or nasopharyngeal swabs. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.